Codis has reached a pivotal milestone in its ongoing expansion project at its Haverhill, UK facility, announcing that demolition of redundant structures is complete, clearing the way for the next phase of construction. This development marks a significant step forward in the company’s investment in a GEA Pharma-SD type PSD-4 solvent-capable spray dryer, a move designed to bolster the company’s capabilities in the pharmaceutical manufacturing sector.
The project is currently tracking according to schedule, with the next critical objective being the Dryer Factory Acceptance Test, which is slated to take place in November. Following that, the facility remains on track to come fully online in the fourth quarter of 2027.
The primary driver behind this expansion is the integration of the PSD-4 unit, which will substantially increase Codis’ commercial-scale solvent-based spray drying capacity for amorphous solid dispersions (ASDs). In the modern pharmaceutical landscape, many new drug candidates face significant challenges related to poor solubility. By scaling up its spray drying capabilities, Codis is positioning itself to better serve its pharmaceutical customers, providing them with the necessary infrastructure to transition these difficult-to-formulate candidates from early-stage development into full-scale commercial manufacturing.
Nick Hodgson, Vice President & General Manager of Haverhill Operations for Codis, emphasized that the decision to build within the existing facility footprint provides strategic advantages. “Completing demolition and moving into construction is an important milestone for the PSD-4 expansion,” said Hodgson. “We can deliver the additional capacity efficiently while building on the expertise and capabilities already in place.”
By utilizing established infrastructure, the company aims to minimize transition risks while maximizing the integration of its new technology. The Haverhill site will play a key role in the company’s broader UK network. While the Haverhill operations focus on these large-scale manufacturing advancements, the company’s integrated network continues to utilize its Nottingham site, which remains the hub for formulation development, analytical services, clinical supply, and oral solid dose capabilities.
This investment underscores Codis’ commitment to meeting the evolving needs of the pharmaceutical industry, particularly as the prevalence of poorly soluble drug compounds continues to rise. By bridging the gap between clinical-scale and commercial-scale manufacturing, Codis is enhancing its ability to support its partners throughout the entire drug development lifecycle.
As construction moves forward, the industry will be watching the Haverhill site closely, as the successful deployment of the PSD-4 will provide a critical service for companies looking to streamline the commercialization of next-generation therapies. With the demolition phase now firmly in the rearview mirror, Codis is well-positioned to meet its 2027 operational target.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
